Associated Papers
A New Cloud-Native Tool for Pharmacogenetic Analysis.
Yuan DY et al.
Genes, 2024
Leveraging in Vitro Models for Clinically Relevant Rare CYP2D6 Variants in Pharmacogenomics.
Stern S et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Characterization of CYP2D6 Pharmacogenetic Variation in Sub-Saharan African Populations.
Twesigomwe D et al.
Clinical Pharmacology and Therapeutics, 2023
Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles.
Chamboko CR et al.
International Journal of Molecular Sciences, 2023
The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data.
Zhou Y et al.
The Pharmacogenomics Journal, 2022
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone).
Matic M et al.
European Journal of Human Genetics : Ejhg, 2022
Characterization of Novel CYP2D6 Alleles across Sub-Saharan African Populations.
Wang WY et al.
Journal of Personalized Medicine, 2022
PacBio long-read amplicon sequencing enables scalable high-resolution population allele typing of the complex CYP2D6 locus.
Charnaud S et al.
Communications Biology, 2022
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Precision Medicine into Clinical Practice: A Web-Based Tool Enables Real-Time Pharmacogenetic Assessment of Tailored Treatments in Psychiatric Disorders.
Zampatti S et al.
Journal of Personalized Medicine, 2021
Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data.
Neyshaburinezhad N et al.
Journal of Personalized Medicine, 2021
Development and Analytical Validation of a 29 Gene Clinical Pharmacogenetic Genotyping Panel: Multi-Ethnic Allele and Copy Number Variant Detection.
Scott SA et al.
Clinical and Translational Science, 2021
Benchmarking analysis of deleterious SNP prediction tools on CYP2D6 enzyme.
Ferreira KCDV et al.
Chemical Biology & Drug Design, 2020
Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6-Mediated Metabolic Activity.
Dalton R et al.
Clinical and Translational Science, 2020
Genetic analysis of pharmacogenomic VIP variants in the Blang population from Yunnan Province of China.
Zhang C et al.
Molecular Genetics & Genomic Medicine, 2019
Feasibility of Integrating Panel-Based Pharmacogenomics Testing for Chemotherapy and Supportive Care in Patients With Colorectal Cancer.
Kasi PM et al.
Technology in Cancer Research & Treatment, 2019
Full-gene haplotypes refine CYP2D6 metabolizer phenotype inferences.
Wendt FR et al.
International Journal of Legal Medicine, 2018
Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics.
Ahmad T et al.
Biochemical Pharmacology, 2018
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.
Zhou Y et al.
Clinical Pharmacology and Therapeutics, 2017
Assessing the capability of massively parallel sequencing for opportunistic pharmacogenetic screening.
Ng D et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2017
Analysis of Genetic Variation in CYP450 Genes for Clinical Implementation.
Goh LL et al.
Plos One, 2017
High Frequency of CYP2D6 Ultrarapid Metabolizer Genotype in the Finnish Population.
Pietarinen P et al.
Basic & Clinical Pharmacology & Toxicology, 2016
Long-Read Single Molecule Real-Time Full Gene Sequencing of Cytochrome P450-2D6.
Qiao W et al.
Human Mutation, 2016
Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity.
Wang D et al.
Human Molecular Genetics, 2014
Advances in molecular modeling of human cytochrome P450 polymorphism.
Martiny VY et al.
Journal of Molecular Biology, 2013
High prevalence of CYP2D6*41 (G2988A) allele in Saudi Arabians.
Al-Dosari MS et al.
Environmental Toxicology and Pharmacology, 2013
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
Clinically relevant genetic variations in drug metabolizing enzymes.
Pinto N et al.
Current Drug Metabolism, 2011
Identification of new alleles and the determination of alleles and genotypes frequencies at the CYP2D6 gene in Emiratis.
Qumsieh RY et al.
Plos One, 2011
Role of cytochrome P450 genotype in the steps toward personalized drug therapy.
Cavallari LH et al.
Pharmacogenomics and Personalized Medicine, 2011
Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population.
Wright GE et al.
Annals of Human Genetics, 2010
CYP2D6 and tamoxifen: DNA matters in breast cancer.
Hoskins JM et al.
Nature Reviews. Cancer, 2009
Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales.
Sistonen J et al.
Pharmacogenetics and Genomics, 2009
Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects.
Matimba A et al.
Human Genomics, 2009
New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme.
Wang B et al.
Drug Metabolism Reviews, 2009
Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans.
Gaedigk A et al.
Clinical Pharmacology and Therapeutics, 2002
Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine.
Marcucci KA et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2002
Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity.
Wennerholm A et al.
Pharmacogenetics, 2001